Zurich immuno-oncology spinout Anaveon raised $35.1m from Novartis Venture Fund and Syncona in addition to seed-stage notes converted by the UZH Life Sciences Fund.

Zurich immuno-oncology spinout Anaveon raised $35.1m from Novartis Venture Fund and Syncona in addition to seed-stage notes converted by the UZH Life Sciences Fund.

Vast Data has emerged from stealth with a total of $80m in funding raised over two rounds from investors such as Dell Technologies Capital.

MIT spinout Ginkgo Bioworks has set up Motif Ingredients with $90m in series A funding provided by investors including Louis Dreyfus Company and Fonterra.

Ginkgo Bioworks has spun out Motif Ingredients with $90m in series A funding provided by investors including Louis Dreyfus Company and Fonterra.

Geneos Therapeutics has received $10.5m in series A funding from investors including its parent company Inovio Pharmaceuticals.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Merck Group and Johnson & Johnson both invested in a $22.6m round for the autoimmune disease drug developer, six years after it was spun off from Merck Serono.

The payment protection software provider received $15m in a round co-led by Microsoft's M12 unit and venture firm Viola Ventures.

The video messaging technology developer has collected $11m in a Kleiner Perkins-led round that also featured existing backer Slack.